BROECKX RUDY LAURENT MARIA,FILLIERS WALTER FERDINAND MARIA,NIESTE PATRICK HUBERT J.,COPMANS ALEX, HERMAN,VANHOUTTE FILIP MARCEL C.,LEYS, CARINA
申请号：
CL2014002385
公开号：
CL2014002385A1
申请日:
2014.09.09
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
There is provided inter alia a dry powder pharmaceutical formulation for inhalation comprising: (i) 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient； (ii) particulate lactose as carrier； and (iii) a particulate stabilizing agent selected from metal salts of stearic acid such as magnesium stearate and metal salts of stearyl fumarate.<；p>；UN MÉ；TODO PARA AUMENTAR LA ESTABILIDAD A LA DEGRADACIÓ；N QUÍ；MICA DE UNA FORMULACIÓ；N FARMACÉ；UTICA QUE CONTIENE 6-(2-((4-AMINO-3-(3-HIDROXIFENIL)-1H-PIRAZOLO[3,4-D]PIRIMIDIN-1-IL)METIL)-3-(2-CLOROBENCIL)-4-OXO-3,4-DIHIDROQUINAZOLIN-5-IL)-N,N-BIS(2-METOXIETIL)HEX-5-INAMIDA Y LACTOSA.<；/p>；
